NZ bathroom fittings company, Methven,
finally has proof their Maia showerhead
can improve people’s eczema – a
claim nobody else in the world can
make. The showerhead was tested on
eczema patients by Clinicanz doctors
and the results were reported in the
New Zealand Medical Journal and on
TV. After announcing it to the stock
exchange, their share price rose 12.5%
in the month following.
Eczema research gives Methven
world beating advantage
Clinicanz Medical Director, Dr Shaun
Holt says Methven did what every
healthcare company should. They took
a series of ‘best guesses’ and patient
feedback to the next level of definitive
scientific proof. Consumers have become
highly educated and stories from friends
and relatives are no longer sufficient.
Companies must be able to back their
claims with scientific evidence. Methven
have set the benchmark for evidence
in theirs and the wider natural health
industry.
Methven developed the Maia showerhead
to reduce chlorine exposure for people
taking showers. Normal ‘town supply’
water contains chlorine to limit bacterial
growth and it was proposed this may be
having an adverse effect on people
with eczema.
The Maia showerhead has a removable
cartridge in the stem of the unit which
contains Vitamin C (ascorbic acid), a
compound known to remove chlorine from
A Final word from Methven
Methven General Manager, HomeSpa division Nicky Dunn says the research has put the
company a step ahead of the competition. “In a competitive market, the research results
give us a unique selling point needed to position Methven as a premium supplier of high
quality bathroom finishings. Our ability to make justifiable medical claims makes a huge
difference for our international business where regulation requires high quality proof.”
“Clinicanz created and ran a quick and effective project and reported the results as soon
as the last patient visit was completed. They went further than other research companies
would, working with Methven to announce the findings